Physician profile
Paul Meier
NPI 1336226968
$2,291.46
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $125 · 2021: $355 · 2022: $647 · 2023: $682 · 2024: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.11 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $313.13 | 2019-2024 | Spravato |
| Tris Pharma INC | $233.17 | 2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $200.72 | 2020-2022 | |
| Lundbeck LLC | $110.87 | 2023-2024 | Rexulti, Brintellix, Abilify Maintena |
| Neos Therapeutics, Lp | $110.31 | 2021-2023 | Adzenys Xr-Odt |
| Corium, LLC | $106.06 | 2022-2023 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.98 | 2022-2024 | Caplyta |
| Allergan, INC. | $75.62 | 2019-2020 | |
| Almatica Pharma LLC | $34.17 | 2023-2024 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $33.22 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $31.53 | 2022-2023 | Quviviq |
| Shire North American Group INC | $29.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.12 | 2022-2024 | Trintellix |
| Eisai INC. | $27.68 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $22.78 | 2019 | |
| Neurocrine Biosciences, INC. | $20.28 | 2024 | Ingrezza |
| Noven Therapeutics, LLC | $17.77 | 2023 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $17.35 | 2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $16.71 | 2022 | |
| Bausch Health US, LLC | $14.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.